Radiofrequency treatment and ablation for nasal obstruction and nasal swell body reduction
Policy governs coverage determination for radiofrequency volumetric tissue reduction (e.g., VivAer Stylus) for internal nasal valve collapse and radiofrequency or cryoablation for nasal swell body reduction for treatment of nasal obstruction.
Annual review April 13, 2026 updated literature through December 18, 2025; policy statements unchanged.
Coverage Summary
Scope: This policy governs coverage determination for radiofrequency volumetric tissue reduction (RFVTR) (e.g., VivAer Stylus) for internal nasal valve collapse and radiofrequency or cryoablation for nasal swell body reduction for treatment of nasal obstruction. Coverage stance: Not covered — procedures considered investigational/cosmetic. Effective date: 2026-05-01. Last review: 2026-04-13.